Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Metagenomi Inc.
Headquarters: Emeryville, CA, United States of America
Website: https://metagenomi.co/
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Brian C. Thomas, PhD
Number Of Employees: 202
Enterprise Value: $-67,448,323
PE Ratio: -0.57
Exchange/Ticker 1: NASDAQ:MGX
Exchange/Ticker 2: N/A
Latest Market Cap: $55,327,600
BioCentury | Jan 29, 2025
Management Tracks
Lyndra names Adam Sayer president and CEO
Plus: Martin Olin becomes CEO of Swarm, and updates from Totus, Nmdp and Vortex
BioCentury | Jul 13, 2024
Management Tracks
CEO moving on from Theolytics
Plus: CSO Luis Borges departs Metagenomi, and updates from Diadem and CureLab
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Feb 13, 2024
Product Development
ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast
Plus: Gilead’s $4.3B takeout of CymaBay
BioCentury | Feb 10, 2024
Finance
Year’s start mostly strong for biotech IPOs
Four of six companies to go public on U.S. exchanges post positive aftermarket moves
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Jan 27, 2024
Finance
Public equity roundup: CG, ArriVent IPOs stoke optimism for growing queue
Plus: Follow-ons for Sagimet, Tourmaline and Adicet, and PIPEs for Kura, ORIC and CalciMedica
BioCentury | Jan 24, 2024
Finance
CG Oncology, ArriVent set to test IPO waters this week
Queue has continued to grow as some investors expect a warming trend for new biotech listings later this year
BioCentury | Jan 13, 2024
Finance
Jan. 12 Quick Takes: Alto Neuroscience files for IPO
Plus: Company-creating research institute Arena BioWorks launches in Kendall Square, and an update from Ji Xing
BioCentury | Jan 12, 2024
Finance
The year of biotech’s recovery
Public Markets Preview: Investors say biotech outperformance in 2024 will hinge on the interest rate environment
Items per page:
1 - 10 of 34